RAFFA WEALTH MANAGEMENT, LLC’s Royalty Pharma RPRX Stock Holding History

RAFFA WEALTH MANAGEMENT, LLC’s Portfolio RPRX Stock Details RPRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-21	Closed	-$916	–	1118
2021 Q1	$916	Hold	21	–	–	﹤0.01%	857
2020 Q4	$1.05K	Buy	+21	New	+$891	﹤0.01%	730

Other funds holding RPRX

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCG

Vantage Consulting Group Virginia Beach, Virginia $19.7M AUM 280.87% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

HMC

Harvard Management Company Boston, Massachusetts $1.82B AUM 26.23% 1-Year Est. Return

SGA

Siguler Guff Advisers New York $56.1M AUM 46.63% 1-Year Est. Return

RAFFA WEALTH MANAGEMENT, LLC's RPRX Position: Q2 2021 in Review

RAFFA WEALTH MANAGEMENT, LLC sold out of Royalty Pharma (RPRX) in Q2 2021, closing a stake of 21 shares — an estimated $916 sold.

RAFFA WEALTH MANAGEMENT, LLC first reported a position in RPRX in Q4 2020 and held it in 2 quarters. The position peaked at $1.05K in Q4 2020. 236 funds tracked by Wall St. Rank hold RPRX as of Q2 2021.

RAFFA WEALTH MANAGEMENT, LLC reported no remaining Royalty Pharma position as of Q2 2021 after selling out during the quarter.
RAFFA WEALTH MANAGEMENT, LLC sold 21 Royalty Pharma shares in Q2 2021, an estimated $916.
RAFFA WEALTH MANAGEMENT, LLC first reported a position in Royalty Pharma in Q4 2020 and held it in 2 quarters.
RAFFA WEALTH MANAGEMENT, LLC's Royalty Pharma position peaked at $1.05K in Q4 2020.
236 funds tracked by Wall St. Rank held Royalty Pharma as of Q2 2021.

Based on RAFFA WEALTH MANAGEMENT, LLC's 13F filing for Q2 2021, filed 27 Jul 2026.